RB1 and breast cancer: Importantly, we provide evidence that human breast cancer (4 different datasets) exhibits a similar organization with P-enriched, M-enriched and S-oncogenic drivers, and have demonstrated that drug combinations targeting S-drivers (RB-loss, MET) plus M-enriched (Rho signaling) cooperate to effectively block cell survival and migration of TNBC cells.